Pediatric Cancer Clinical Trials
Clinical trials evaluate the safety and effectiveness of potential diagnostic tests, treatments, risk reduction methods, and quality of life improvements. Today’s treatments for pediatric cancer were made possible through past clinical trials.
As a medical research institution, UT Southwestern conducts frequent clinical trials, providing our patients with access to the newest treatments before they are available elsewhere. Through their participation, our patients also help advance cancer care and contribute to scientific breakthroughs.
Through our relationship with the Children’s Oncology Group (COG), a National Cancer Institute-supported clinical trials group, our pediatric oncologists have access to the latest treatments, information, and support from all over the world.
U.S. News & World Report’s Best Children’s Hospital 2021-2022 list ranks our pediatric cancer program No. 22 in the nation.
Highlights of clinical trials include:
- Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T-Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
- Study Of Palbociclib Combined With Chemotherapy in Pediatric Patients With Recurrent/Refractory Solid Tumors
- A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=) 1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-Cell or T-Cell Acute Lymphoblastic Leukemia
Learn more about these trials and see all childhood cancer trials available at UT Southwestern.